SCHEMBL537370

SCHEMBL537370

COC(=O)c1ccc2[nH]c(-c3cccnc3OC)cc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.51
HTT P42858 1/20 0.51
LOXL2 Q9Y4K0 1/20 0.47
HDAC6 Q9UBN7 2/20 0.47
PPARG P37231 1/20 0.45
PDE10A Q9Y233 2/20 0.44
SLC40A1 Q9NP59 1/20 0.43
F2 P00734 3/20 0.43
F10 P00742 3/20 0.43
PLG P00747 3/20 0.43
PLAU P00749 3/20 0.43
PLAT P00750 3/20 0.43
PRSS1 P07477 2/20 0.43
BTK Q06187 1/20 0.41
CYP19A1 P11511 1/20 0.41
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL537661 0.89 PPARG (0.48) LOXL2HDAC6PPARGPDE10AF2
SCHEMBL4884350 0.82 HTT (0.49) ALOX15HTTPDE10AF2F10
SCHEMBL5448565 0.80 ITK (0.54) ALOX15LOXL2PPARGBTKIDH1
SCHEMBL537355 0.79 RAB9A (0.61) ALOX15LOXL2PDE10ABTKCYP19A1
SCHEMBL537286 0.76 CYP2C9 (0.54) ALDH1A1HPGD
SCHEMBL2773294 0.75 HTT (0.51) ALOX15HTTHDAC6PDE10ASLC40A1
SCHEMBL26088530 0.75 LOXL2 (0.47) LOXL2PDE10AF2BTKCYP19A1
SCHEMBL976938 0.75 F2 (0.59) HDAC6PPARGF2F10PLG
SCHEMBL16502454 0.75 HTT (0.54) ALOX15HTTHDAC6PDE10ASLC40A1
SCHEMBL4964321 0.73 HDAC6 (0.57) ALOX15HTTHDAC6PDE10AF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410144-B2 Substituted indolo-pyridinone compounds ARQULE, INC. (US) 2013-04-02 US disclosed
US-8410144-B2 Substituted indolo-pyridinone compounds ARQULE, INC. (US) 2013-04-02 US disclosed
US-8410144-B2 Substituted indolo-pyridinone compounds ARQULE, INC. (US) 2013-04-02 US disclosed
EP-2414344-A1 SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS ArQule, Inc. (US) 2012-02-08 EP disclosed
WO-2010114896-A1 SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS ARQULE, INC. (US) 2010-10-07 WO disclosed
WO-2010114896-A1 SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS ARQULE, INC. (US) 2010-10-07 WO disclosed
US-20100249127-A1 SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249127-A1 SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249127-A1 SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249127-A1 SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS MKI67, CCNI, CDK4 ALOX15 857/4885HTT 1326/4885LOXL2 3300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.